Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer Aviation Inc (ACHR) vs BioNano Genomics Inc (BNGO) Price & Performance

Archer Aviation IncTrade
BioNano Genomics IncTrade

Price performance (Past 24H)

Key statistics

Archer Aviation Inc vs BioNano Genomics Inc — how do they compare? Archer Aviation Inc trades at $6.3 (market cap $5.23B), while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: Archer Aviation Inc is far larger — about 382.9× BioNano Genomics Inc's market cap, and Archer Aviation Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

ACHRBNGO
Market Cap
$5.23B$13.66M
Sector
IndustrialsHealth
52-Week High
$13.64$4.92
52-Week Low
$4.44$1.06
Enterprise Value
$3.79B$16.26M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer Aviation Inc

Archer Aviation (ACHR) trades at $6.29, up 0.48% with strong technical momentum and bullish analyst sentiment. The company reported Q2 2026 revenue of $5 million, beating expectations by 150%, while announcing a transformative Boeing deal acquiring three businesses for a 20% equity stake. Despite negative profitability metrics and substantial cash burn, the strategic expansion into defense and autonomous aviation technology has driven recent stock appreciation.

The outlook remains speculative with significant execution risks, but strategic partnerships and regulatory progress provide potential upside. Investors face dilution concerns from the $750 million equity offering while betting on long-term commercialization of air taxi technology. The stock's valuation appears stretched with P/S ratio of 719.85, requiring successful commercialization to justify current levels.

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

Read more on ACHR

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO